@article{Cai2026, 
author = {Zengzhi Cai and Fan Chen and Ying Jin and Feng Wang},
title = {Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025},
year = {2026},
journal = {Cancer Innovation},
volume = {5},
number = {2},
pages = {e70057},
keywords = {BRAF V600E mutation, circulating tumor DNA, colorectal cancer, HER2 amplification, immunotherapy, KRAS G12C mutation, microsatellite instability, minimal residual disease, precision medicine, targeted therapy},
url = {https://www.sciopen.com/article/10.1002/cai2.70057},
doi = {10.1002/cai2.70057},
abstract = {This review summarizes landmark advances in colorectal cancer treatment in 2025, characterizing the transition to dynamic precision oncology. Immunotherapy has revolutionized mismatch repair‐deficient or microsatellite instability‐high patients, becoming the standard first‐line and perioperative regimen. Precision medicine expanded to patients with BRAF V600E, KRAS mutation, and HER2 amplification. While circulating tumor DNA utility was confirmed for surveillance and guiding rechallenge, its role in real‐time treatment adjustment continues to be explored.}
}